Payment overview · 2025
General Payments
$98.98
5 reported records · 5 companies
Healthcare provider profile · identity verified
Jared K Wilson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LIBERTY, KY · NPI 1902876667
Verified facts
What the public records show
CMS Open Payments records show Jared K Wilson, M.D. received $98.98 in general payments during 2025 across 5 reported records.
Vanda Pharmaceuticals Inc. accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.95 | 31.3% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $21.93 | 22.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.89 | 18.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.22 | 14.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.99 | 14.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $98.98 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 398 | 42 |
| Omeprazole | Omeprazole | 347 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 54 |
| Gabapentin | Gabapentin | 290 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 41 |
| Metformin Hcl | Metformin Hcl | 245 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 44 |
| Lisinopril | Lisinopril | 233 | 41 |
| Losartan Potassium | Losartan Potassium | 205 | 31 |
| Furosemide | Furosemide | 202 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 192 | 27 |
| Potassium Chloride | Potassium Chloride | 180 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 29 |
| Trazodone Hcl | Trazodone Hcl | 166 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 146 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 30 |
| Prednisone | Prednisone | 126 | 73 |
| Ropinirole Hcl | Ropinirole Hcl | 126 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 30 |
| Clonazepam | Clonazepam | 122 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 122 | 12 |
| Clonidine Hcl | Clonidine Hcl | 118 | 28 |
| Alprazolam | Alprazolam | 117 | 11 |
| Baclofen | Baclofen | 115 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 115 | 16 |
| Ondansetron Odt | Ondansetron | 114 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 21 |
| Montelukast Sodium | Montelukast Sodium | 113 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 20 |
| Eliquis | Apixaban | 111 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 24 |
| Carvedilol | Carvedilol | 106 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 21 |
| Ibuprofen | Ibuprofen | 101 | 19 |
| Promethazine Hcl | Promethazine Hcl | 99 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 98 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 33 |
| Diazepam | Diazepam | 95 | suppressed |
| Mirtazapine | Mirtazapine | 95 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 16 |
| Ozempic | Semaglutide | 93 | 13 |
| Meloxicam | Meloxicam | 90 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 16 |
| Simvastatin | Simvastatin | 80 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 15 |
| Ezetimibe | Ezetimibe | 78 | 13 |
| Famotidine | Famotidine | 75 | 11 |
| Buspirone Hcl | Buspirone Hcl | 74 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 11 |
| Cephalexin | Cephalexin | 69 | 44 |
| Levofloxacin | Levofloxacin | 68 | 36 |
| Azithromycin | Azithromycin | 64 | 47 |
| Fluconazole | Fluconazole | 64 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 61 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 57 | 39 |
| Sertraline Hcl | Sertraline Hcl | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | suppressed |
| Sucralfate | Sucralfate | 52 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 34 |
| Donepezil Hcl | Donepezil Hcl | 50 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Nitroglycerin | Nitroglycerin | 48 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Nystatin | Nystatin | 47 | 15 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Loperamide | Loperamide Hcl | 43 | 20 |
| Estradiol | Estradiol | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 12 |
| Azelastine Hcl | Azelastine Hcl | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 11 |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 17 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 17 |
| Risperidone | Risperidone | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 17 |
| Hydrocortisone | Hydrocortisone | 25 | 16 |
| Lidocaine | Lidocaine | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Etodolac | Etodolac | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Ursodiol | Ursodiol | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lanoxin | Digoxin | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Felbamate | Felbamate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $98.98 · 5 records | Vanda Pharmaceuticals Inc. | ETERNA, FANAPT, NURTEC ODT, Natroba, QULIPTA, Spinosad, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error